Literature DB >> 1676068

DNA strand breakage by peroxidase-activated mitoxantrone.

G R Fisher1, L H Patterson.   

Abstract

Spectroscopic evidence demonstrate that the alkylaminoanthraquinone mitoxantrone is a substrate for horseradish peroxidase in the presence of hydrogen peroxide and that the result of this interaction is the formation of an air-stable mitoxantrone-derived free radical. The mitoxantrone-derived free radicals or their further oxidation products appear to extensively cross-link with plasmid DNA by a reaction that is mitoxantrone concentration-dependent. Oxidative activation of mitoxantrone to a DNA-damaging species may contribute to the mechanism of action of this antitumour agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676068     DOI: 10.1111/j.2042-7158.1991.tb05455.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors.

Authors:  M Senkal; J C Tonn; R Schönmayr; W Schachenmayr; U Eickhoff; M Kemen; E Kollig
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 2.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

3.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

5.  Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.

Authors:  A Skladanowski; J Konopa
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

Review 6.  Emerging small-molecule treatments for multiple sclerosis: focus on B cells.

Authors:  Aaron Gregson; Kaitlyn Thompson; Stella E Tsirka; David L Selwood
Journal:  F1000Res       Date:  2019-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.